secwatch.observer — SEC 8-K summary
======================================

Issuer:     Paratek Pharmaceuticals, Inc. (—)
CIK:        0001178711
Form:       8-K
Filed at:   2023-09-21T23:59:59+00:00
Accession:  0001193125-23-239185
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 1.02, 2.01, 2.03, 3.01, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gurnet Point and Novo Holdings complete acquisition of Paratek for $2.15/share cash + $0.85 CVR
--------------------------------------------------------------------------------

- Total enterprise value ~$462M including assumed debt and full CVR payment.
- Stockholders approved merger on Sept 18; deal closed Sept 21, 2023.
- Paratek common stock to be delisted from Nasdaq; company becomes private.
- CVR of $0.85/share payable if U.S. NUZYRA net sales reach $320M by Dec 31, 2026.
- All prior directors resigned; Stacy Seltzer and Adam Dilluvio appointed as new directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178711/000119312523239185/0001193125-23-239185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178711/000119312523239185/d524523d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-239185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer